Paraoxonase 1 (PON1) requires calcium for activity and is inactivated in the presence of EDTA. Because of this, studies to date have used serum or heparinized plasma for both activity and mass assays of PON1.
Introduction
Human paraoxonase 1 (PON1) is a calcium-dependent serum enzyme that is found in association with high density lipoproteins (HDL) (1) . PON1 has a variety of substrates and has been found to have multiple polymorphisms in both the coding sequence (L55M, Q192R) and in the non-coding sequence (2) . Promoter polymorphisms, notably -108C/T (also referred to as -107C/T) and -162A/G have been shown to affect PON1 expression (3) (4) (5) .
Substrates, such as paraoxon, which are hydrolyzed at different rates by PON1 Q192 versus PON1 R192, have been used to phenotype PON1 and to determine possible sensitivity to organophosphate pesticides (3) . However, these substrates are not of use for determining the mass of PON1 in serum.
Arylesterase activity in human serum, measured using phenyl acetate hydrolysis, is expressed similarly by the known PON1 polymorphic forms and has been used as a surrogate for PON1 mass (1) .
The first reported analysis of PON1 mass in normal subjects was by Blatter Garin et al. who compared subjects from Geneva and Manchester and identified significant differences in PON1 Q192R allele frequency, PON1 enzyme activity and PON1 mass (6) . Studies of PON1 knockout and transgenic mice, and of human populations, are consistent with PON1 having a protective function in organophosphate toxicity and cardiovascular disease (7, 8) . Although PON1 is thought to be tightly associated with apolipoprotein AI (apoAI), the concentration and activity of PON1 has been consistently reported to vary over a wider range than that observed for apoAI. This variation may, in part, be the result of by guest, on October 14, 2017 www.jlr.org Downloaded from environmental factors. For example, smoking (inversely) (9) and moderate alcohol intake (positively) (10) have been reported as determinants of PON1.
Investigation of PON1 using EDTA plasma has been actively discouraged because of the loss of enzyme activity in the presence of EDTA due to the removal of calcium from the enzyme. Because a number of studies have only EDTA plasma samples available, we considered that it would be of value to develop an assay for PON1 mass to allow application to a broader range of investigations. We report here the validation of an assay for PON1 mass in EDTA samples.
Materials and Methods

SDS-electrophoresis
Polyacrylamide gels (8% acrylamide, 29:1 ratio of acrylamide to bis-acrylamide) containing 12 wells, prepared in Novex cassettes, were used for the separation of components of serum and EDTA plasma. An 80-fold dilution of serum or plasma was made with 60 mM Tris pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 50 mM dithiothreitol and heated at 95 °C for 5 mins. A 10 µl volume of sample was loaded into each well (equivalent to 125 nl of serum). Recombinant human paraoxonase 1 (rHuPON1) with an amino terminus hexa-histidine tag, was purchased from Cedarlane Laboratories (Hornby, Ontario, Canada) and was Michael's Lipid Clinic were used to assess the potential interference from lipemia.
Apolipoprotein AI and B were assayed using the Dade-Behring BN100 Plasma Protein analyzer. Cholesterol and triglyceride were assayed using a Hitachi 917 random-access analyzer and Roche reagents. HDL cholesterol was assayed in the supernatant after dextran sulfate -Mg 2+ precipitation. All lipid assays were standardized by the National Heart Lung and Blood Institute-Centers for Disease
Control Lipid Standardization Program, Atlanta, GA.
Statistical analysis
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Statistical analysis was performed with GraphPad Prism version 5.0 (GraphPad, San Diego, CA).
Results
Western blot analysis, using anti-human mouse PON1 monoclonal antibody 4C10, for a serum -plasma pair, is shown in Figure 1 . The advantage of using the pre-stained gel markers can be seen as they are detectable by for each set of Western blots and was used to assign a target value to the reference plasma.
We evaluated between-day variation as follows. Each day samples were loaded on four gels with one gel containing the molecular weight marker in the outside lanes and plasma calibrator samples in duplicate and an eight point standard curve. The remaining three gels contained the molecular weight marker in the outside lanes, the plasma calibrator sample in duplicate and each unknown (study subject) sample in duplicate. Thus 15 unknown samples are assayed per four gels. One technician can routinely run eight gels per day. The results for the plasma calibrator run on four separate days and on seven gels per day are shown in Figure 3 . By two-way analysis of variance, between-day variance accounted for 58% of the variation (p < 0.0001) and between-gel variance accounted for 28% of the variation (p = 0.0017) in the reference plasma sample.
The within-day coefficient of variance ranged from 1.9% to 6.6% and the coefficient of variance for all analyses was 7.8%. The mean value of 236 μg/ml was assigned to the reference plasma and used as the calibrator for each gel.
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We examined the relationship between PON1 mass, activity and lipoprotein concentrations. Serum PON1 mass explained 72% of the variation in PON1 arylesterase activity. Plasma PON1 mass explained 77% of the variation in PON1 arylesterase activity. Of the lipid and lipoprotein variables (Table 1) , only HDL cholesterol (8%) or apoAI (7.2%) contributed significant additional information (p < 0.03) with regards to the variation in arylesterase activity.
The proportion of the minor PON1 band was relatively constant over the range of the PON1 concentration with a correlation of 0.85 (p<0.0001) ( Figure 5 ).
However, the intensity of the minor band was near the value of the lowest standard and should therefore be considered an approximate value.
The interference by high concentrations of triglycerides was tested since there may be an upper limit to the solubilization of triglycerides by SDS. The protocol followed for the results shown in Figure mM did not affect the assay ( Figure 6D ).
Discussion
The method described here for the quantification of PON1 has several important features: 1) the method is sensitive, using only nl quantities of serum or plasma; 2) the use of infrared fluorescence for the detection and quantification provides a signal which is stable over time and linear allowing the scanning of the blots to be carried out at a convenient time; 3) the method allows the use of a single primary antibody, either monoclonal or polyclonal.
The use of an ELISA for the quantification of PON1 mass was first reported in 1994 (6). The method was calibrated using purified PON1 and
Western blot. The current method improves and extends the original method as outlined above. Because of the limited accessibility of mass assays for PON1 (13) , many studies restrict analysis of PON1 to activity measurements. It has been suggested that measurement of PON1 should routinely include the concentration of the enzyme (14) . The relative importance of enzymatic activity,
as assessed by hydrolysis of a selected substrate under saturating conditions, enzyme mass, and enzyme specific activity remains to be determined. Some studies have found differences in all, some or only one of these characteristics (6, 9, (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Recently, is has been reported that PON1 mass inversely predicts mortality in patients on hemodialysis (27) . Thus the indications for the measurement of the mass of PON1 continue to expand. Measurement of PON1 will facilitate its use as a biomarker to predict risk for vascular disease. Figure 1 . SDS-electrophoresis and Western blot for PON1 in serum, citrated plasma and EDTA plasma. Abbreviations: MW STD, molecular weight standard; hsPON1, PON1Q192 purified from human serum; Serum, human serum collected without anti-coagulants; citrate -human plasma collected in the presence of citrate anti-coagulant; EDTA, human plasma collected in the presence of EDTA anti-coagulant. 
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